eptinezumab

Details

Files
Generic Name:
eptinezumab
Project Status:
Complete
Therapeutic Area:
Migraine
Manufacturer:
Lundbeck Canada Inc.
Brand Name:
Vyepti
Project Line:
Reimbursement Review
Project Number:
SR0743-000
NOC Status at Filing:
Post NOC
Performance Metric:
Achieved
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the prevention of migraine in adults who have at least four migraine days per month and have experienced an inadequate response, intolerance, or contraindication to at least two oral prophylactic migraine medications.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
​For the prevention of migraine in adults who have at least 4 migraine days per month.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2
Call for patient/clinician input openMay 11, 2022
Call for patient/clinician input closedJuly 04, 2022
Clarification:

- Patient input submission received from Migraine Canada & Migraine Quebec

Submission receivedJune 08, 2022
Submission accepted
Review initiatedJune 23, 2022
Draft CADTH review report(s) provided to sponsor for commentSeptember 08, 2022
Deadline for sponsors commentsSeptember 19, 2022
CADTH review report(s) and responses to comments provided to sponsorOctober 14, 2022
Expert committee meeting (initial)October 26, 2022
Draft recommendation issued to sponsorNovember 08, 2022
Draft recommendation posted for stakeholder feedbackNovember 17, 2022
End of feedback periodDecember 01, 2022
Final recommendation issued to sponsor and drug plansDecember 15, 2022
Final recommendation postedJanuary 10, 2023
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)January 06, 2023
CADTH review report(s) postedMarch 15, 2023